• Clinical Mass Spectrometry Laboratory

    The Clinical Mass Spectrometry Laboratory recognizes your requirements for timelines, data accuracy  and data accessibility to make critical decisions affecting your compounds’ progress toward marketability.

    The Clinical Mass Spectrometry Laboratory provides an analytical resource focusing on the application of mass spectrometry and allied chromatographies to the analysis of small molecules, generally of less than 1,000 daltons molecular weight, in complex clinical and biological samples. The goals of the program are to better understand the biochemical basis of disease, to improve diagnostic approaches to detection of early-stage disease and to explore mechanisms that lead to improved treatments or prevention.

  • Our leadership in innovative compound development is demonstrated by:

    • Service
    • Scientific excellence
    • Regulatory compliance and guidance
    • Investment
    • Capacity
    • GLP capabilities

    Our scientists develop and validate many methods using a variety of instrumental techniques. We develop both proprietary and nonproprietary methods according to our clients’ needs. We offer flexibility to make adjustments to the protocol and report format according to your requirements. From late discovery pharmacokinetic studies through phase III trials, we have the scientific and operational excellence to deliver on-time accurate data.

    We are equipped with a high-resolution VG Autospec Q  GC-MS-MS instrument, a Micromass LC Quattro Electrospray Triple quadrupole instrument and two Waters Micro LC-MS instruments. These instruments are complemented with four capillary column gas chromatography instruments and four high-pressure liquid chromatography (HPLC) systems having ultraviolet, fluorescence and electrochemical detectors that are available for method development and analytical support.

    The Mass Spectrometry Laboratory is a resource to assist you with many types of testing.

    • Sirolimus
    • Tacrolimus
    • Fast atom bombardment ionization mass spectrometry (FAB-MS) of urinary bile acids for detection of inborn errors in bile acid synthesis
    • Plasma topiramate (Topamax)
    • Acylcarnitine
    • Serum bile acids by GC-MS
    • Risperidone
    • Organic acids
    • Assay development